Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium

[1]  D. Ståhl,et al.  Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine , 2022, Journal of psychopharmacology.

[2]  D. Rujescu,et al.  Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia , 2022, JAMA psychiatry.

[3]  M. Fornaro,et al.  Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia , 2021, Early intervention in psychiatry.

[4]  J. MacCabe,et al.  Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis , 2021, The British Journal of Psychiatry.

[5]  A. Egerton,et al.  Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis , 2021, Psychological Medicine.

[6]  M. D. Forti,et al.  Predicting onset of early- and late-treatment resistance in first-episode schizophrenia patients using advanced shrinkage statistical methods in a small sample , 2020, Psychiatry Research.

[7]  W. Honer,et al.  Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders. , 2020, Schizophrenia bulletin.

[8]  R. Emsley,et al.  Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA) , 2020, Schizophrenia bulletin.

[9]  Peter B. Jones,et al.  Prevalence of treatment resistance and clozapine use in early intervention services , 2020, BJPsych Open.

[10]  S. Kymes,et al.  A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States , 2020, PloS one.

[11]  R. Murray,et al.  Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies , 2019, Psychological Medicine.

[12]  J. MacCabe,et al.  Stratified medicine in schizophrenia: how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life? , 2019, The European Journal of Health Economics.

[13]  J. Geddes,et al.  A systematic review and meta‐analysis of clinical predictors of lithium response in bipolar disorder , 2019, Acta psychiatrica Scandinavica.

[14]  G. Kirov,et al.  Clinical indicators of treatment-resistant psychosis , 2019, The British Journal of Psychiatry.

[15]  J. Haro,et al.  Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study , 2019, Psychiatry Research.

[16]  Isabelle Guyon,et al.  Biases in feature selection with missing data , 2019, Neurocomputing.

[17]  M. Palermo,et al.  Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis , 2019, Front. Psychiatry.

[18]  David Benrimoh,et al.  A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. , 2019, Journal of affective disorders.

[19]  M. Tai,et al.  Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics , 2018, BMC Psychiatry.

[20]  M. Fornaro,et al.  Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses , 2018, Psychiatry Research.

[21]  F. Iasevoli,et al.  Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs , 2018, Front. Psychiatry.

[22]  D. Velligan,et al.  Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study , 2018, BMC Psychiatry.

[23]  J. Lieberman,et al.  A predictive model for conversion to psychosis in clinical high-risk patients , 2018, Psychological Medicine.

[24]  T. Patterson,et al.  Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients , 2018, Schizophrenia Research.

[25]  S. Geer,et al.  Statistics for big data: A perspective , 2018 .

[26]  M. Hotopf,et al.  Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure , 2018, Schizophrenia bulletin.

[27]  Alice Mulè,et al.  Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study , 2017, JAMA psychiatry.

[28]  A. Meyer-Lindenberg,et al.  Machine Learning for Precision Psychiatry: Opportunities and Challenges. , 2017, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[29]  John B. Carlin,et al.  Model checking in multiple imputation: an overview and case study , 2017, Emerging Themes in Epidemiology.

[30]  G. Breen,et al.  Multi-polygenic score approach to trait prediction , 2017, Molecular Psychiatry.

[31]  V. Siskind,et al.  Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis , 2017, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[32]  J. Miettunen,et al.  Age at onset and the outcomes of schizophrenia: A systematic review and meta‐analysis , 2017, Early intervention in psychiatry.

[33]  Peter J. McKenna,et al.  Evaluation of machine learning algorithms and structural features for optimal MRI-based diagnostic prediction in psychosis , 2017, PloS one.

[34]  R. Murray,et al.  Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors , 2017, Psychological Medicine.

[35]  H. Möller,et al.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. , 2017, The American journal of psychiatry.

[36]  C. G. Berardo,et al.  Burden of illness of people with persistent symptoms of schizophrenia: A multinational cross-sectional study , 2017, The International journal of social psychiatry.

[37]  B. Carpiniello,et al.  Duration of untreated illness as a key to early intervention in schizophrenia: A review , 2016, Neuroscience Letters.

[38]  R. Murray,et al.  Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses , 2016, Psychological Medicine.

[39]  M. Matějka,et al.  Altered Neural Correlate of the Self-Agency Experience in First-Episode Schizophrenia-Spectrum Patients: An fMRI Study. , 2016, Schizophrenia bulletin.

[40]  C. Gasse,et al.  Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. , 2016, The lancet. Psychiatry.

[41]  P. McGuire,et al.  Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis , 2016, Schizophrenia bulletin.

[42]  Heejung Bang,et al.  How to Establish Clinical Prediction Models , 2016, Endocrinology and metabolism.

[43]  D. D. Berardis,et al.  Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[44]  B. Misiak,et al.  Profiling cognitive impairment in treatment-resistant schizophrenia patients , 2016, Psychiatry Research.

[45]  Gareth Ambler,et al.  Review and evaluation of penalised regression methods for risk prediction in low‐dimensional data with few events , 2015, Statistics in medicine.

[46]  D. Rujescu,et al.  Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. , 2015, The American journal of psychiatry.

[47]  R. Emsley,et al.  Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia , 2015, Human psychopharmacology.

[48]  Gary S Collins,et al.  Transparent reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. , 2015, Journal of clinical epidemiology.

[49]  P. Austin,et al.  Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models , 2014, Statistical methods in medical research.

[50]  Stephanie Warnez,et al.  Clozapine: a review of clinical practice guidelines and prescribing trends , 2014, BMC Psychiatry.

[51]  C. Altar,et al.  The social and economic burden of treatment-resistant schizophrenia: a systematic literature review , 2014, International clinical psychopharmacology.

[52]  Eva Petkova,et al.  A comparative study of variable selection methods in the context of developing psychiatric screening instruments , 2014, Statistics in medicine.

[53]  F. Iasevoli,et al.  Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: Correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses , 2013, Psychiatry Research.

[54]  K. Do,et al.  Treatment and Early Intervention in Psychosis Program (TIPP‐Lausanne): implementation of an early intervention programme for psychosis in Switzerland , 2013, Early intervention in psychiatry.

[55]  Mark I McCarthy,et al.  Data sharing in large research consortia: experiences and recommendations from ENGAGE , 2013, European Journal of Human Genetics.

[56]  Max Kuhn,et al.  Applied Predictive Modeling , 2013 .

[57]  Richard D Riley,et al.  Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes , 2013, BMJ : British Medical Journal.

[58]  T. Insel,et al.  Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? , 2012, Molecular Psychiatry.

[59]  M. Knapp,et al.  Effective Interventions in schizophrenia: the economic case. , 2012 .

[60]  Shitij Kapur,et al.  Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation , 2012, British Journal of Psychiatry.

[61]  D. Berardi,et al.  First-episode psychosis at the West Bologna Community Mental Health Centre: results of an 8-year prospective study , 2012, Psychological Medicine.

[62]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[63]  A. Üçok,et al.  Remission after first-episode schizophrenia: Results of a long-term follow-up , 2011, Psychiatry Research.

[64]  Peter Bühlmann,et al.  MissForest - non-parametric missing value imputation for mixed-type data , 2011, Bioinform..

[65]  Constantine Frangakis,et al.  Multiple imputation by chained equations: what is it and how does it work? , 2011, International journal of methods in psychiatric research.

[66]  G. Krarup,et al.  Predictors of recovery from psychosis Analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5years , 2011, Schizophrenia Research.

[67]  Galit Shmueli,et al.  To Explain or To Predict? , 2010, 1101.0891.

[68]  J. Rabinowitz,et al.  Trajectories and antecedents of treatment response over time in early-episode psychosis. , 2010, Schizophrenia bulletin.

[69]  B. Mulsant,et al.  Age at onset and cognition in schizophrenia: meta-analysis , 2009, British Journal of Psychiatry.

[70]  Ofer Harel,et al.  The estimation of R 2 and adjusted R 2 in incomplete data sets using multiple imputation , 2009 .

[71]  S. Cooper,et al.  Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. , 2009, The British journal of psychiatry : the journal of mental science.

[72]  C.J.H. Mann,et al.  Clinical Prediction Models: A Practical Approach to Development, Validation and Updating , 2009 .

[73]  E. Steyerberg.  Clinical Prediction Models , 2008, Statistics for Biology and Health.

[74]  S. Hutton,et al.  Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia , 2008, The British journal of psychiatry : the journal of mental science.

[75]  J. Vázquez-Barquero,et al.  Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. , 2007, Journal of psychiatric research.

[76]  C. Shields,et al.  Schizophrenia: a review. , 2007, American family physician.

[77]  R. Emsley,et al.  Remission in first-episode psychosis: predictor variables and symptom improvement patterns. , 2006, The Journal of clinical psychiatry.

[78]  Andrew J Vickers,et al.  Selecting patients for randomized trials: a systematic approach based on risk group , 2006, Trials.

[79]  N. Perkins,et al.  The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. , 2006, American journal of epidemiology.

[80]  A. Malla,et al.  Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study , 2006, Psychological Medicine.

[81]  A. Malla,et al.  Is adolescent-onset first-episode psychosis different from adult onset? , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[82]  Ewout W Steyerberg,et al.  Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements. , 2004, Journal of clinical epidemiology.

[83]  Eric R. Ziegel,et al.  The Elements of Statistical Learning , 2003, Technometrics.

[84]  C. Benkelfat,et al.  Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers , 2002, Schizophrenia Research.

[85]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[86]  J. Lieberman,et al.  Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. , 1995, The American journal of psychiatry.

[87]  G. Wilkening.  Age at onset , 1965, Encyclopedia of Autism Spectrum Disorders.

[88]  Lena Osterhagen,et al.  Multiple Imputation For Nonresponse In Surveys , 2016 .

[89]  D. Veale,et al.  National Collaborating Centre for Mental Health , 2006 .

[90]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.